Novartis pays $245M to settle Exforge generic pay-for-delay suit
Novartis' Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis - PMLiVE
Novartis to pay $35 million to settle charges of illegally promoting a drug for infants
SIX NOVARTIS BI-FOLDERS 2007 RARE DRUG REP PROMO | eBay
Novartis And UK Launch Partnership On Groundbreaking Cardiovascular Prevention Trial :: Scrip
Novartis to Spin Off, List Sandoz Drugs Business - WSJ
Reinventing Pharma | Reuters Events | Pharma
VOGT - Sanaa Building - Novartis Campus, Basel
Malaria Futures for Asia | Novartis
Six Novartis Korea Managers Indicted Over Illegal Payments to Doctors - WSJ
Naveen Gullapalli - Global Head, Novartis Business Services Innovation (NBS X) - Novartis | LinkedIn
Novartis' Zykadia nears first-line lung cancer label - PMLiVE
Teva Pharma appoints Novartis, Biogen vet as new president and CEO – PharmaLive
Novartis to prioritise U.S. market, unfazed by drug pricing pushback | Reuters
Hans Fritz at Novartis Thailand (B): The First Six Months
Six Former and Current Novartis AG Execs Charged With Bribing Doctors in Korea | BioSpace
Novartis - Wikipedia
Novartis Aktie News: Novartis behauptet sich am Vormittag | 07.03.23 | finanzen.ch
Novartis Aktie News: Novartis verliert am Donnerstagvormittag | 09.03.23 | finanzen.ch
Novartis halts Pluvicto new patient starts amid supply struggle
